Insights

Designing a Co-Crystal Screening Program: A Practical Checklist

A practical, step-by-step framework for teams who need defensible solid-form data, not just a longer polymorph report.

13 November 2026 4 min read PCL Research & Manufacturing
Designing a Co-Crystal Screening Program: A Practical Checklist

Too many co-crystal programs start with a coformer list pulled from a textbook and end with a form nobody can scale or patent. The gap between ‘we found a co-crystal’ and ‘we have a developable, protectable solid form’ is where most timelines and budgets quietly disappear.

1. Lock the Target Product Profile Before Screening Anything

Before selecting a single coformer, write down what the co-crystal actually needs to fix: solubility, dissolution rate, hygroscopicity, mechanical properties, or chemical stability. This defines your screening criteria and your go/no-go thresholds from day one.

Skipping this step is the most common and most expensive mistake we see. Teams generate a library of interesting new crystal forms with no way to rank them against the original problem, because nobody defined what ‘better’ meant before the work started.

2. Build a Rational Coformer Shortlist, Not a Random One

Use the API’s hydrogen-bonding functional groups, pKa, and known supramolecular synthons to shortlist coformers with genuine complementarity to the molecule. Cross-reference GRAS status and prior regulatory precedent if the compound is intended for clinical development.

A shortlist of 15–25 structurally rational candidates, informed by crystal engineering principles, consistently outperforms a brute-force screen of 50+ coformers chosen mainly because they were on hand in the lab.

3. Match the Screening Method to the Molecule and the Timeline

Solvent-drop grinding, slurry conversion, solution crystallization, and melt methods each reveal different parts of the co-crystal landscape. For high-potency or controlled substance APIs, method choice also has direct consequences for containment and handling, which should be planned in parallel with the chemistry.

At PCL Research & Manufacturing, screening protocols are built around the specific compound rather than applied as a fixed template, because a rigid one-size-fits-all method frequently misses the thermodynamically relevant form for a given molecule.

4. Confirm the Form Rigorously Before You Call It a Co-Crystal

A new XRPD pattern is a hypothesis, not a conclusion. Confirm true co-crystal formation with a combination of XRPD, DSC, TGA, and, where needed, solid-state NMR or Raman spectroscopy, and verify stoichiometry and phase purity before moving forward.

This stage is where premature reporting creates downstream risk: a form later reclassified as a physical mixture, salt, or solvate can undermine both development timelines and any IP position already built around it.

5. Build the IP Strategy in Parallel, Not After the Screen

Patent counsel should be looped in once a shortlist of confirmed forms exists, not after a single lead has already been chosen. Novel co-crystals with demonstrated functional advantages (stability, solubility, manufacturability) are patentable assets in their own right, independent of the parent API patent.

Running the IP conversation in parallel with characterization lets you prioritize forms with both technical merit and claim strength, rather than discovering late that your preferred form has weak or contested novelty.

6. Decide What to Scale, and Set a Clear Stop Point

Not every confirmed co-crystal deserves scale-up. Apply your original target product profile criteria to rank candidates, then confirm scalability with stability screening under ICH-relevant conditions and a small, representative crystallization run.

Programs without a defined stop point tend to keep generating ‘interesting’ forms indefinitely. A disciplined screening program ends with a documented decision, not an open-ended list of candidates still awaiting a final call.

A well-designed co-crystal screening program is as much about discipline and sequencing as it is about chemistry — the molecules rarely fail, but the process around them often does. If your team is scoping a co-crystal program, or reassessing one that has stalled, we are happy to discuss how a structured, data-driven approach could apply to your specific molecule. Reach out to the team at PCL Research & Manufacturing to start the conversation.

Share

More insights

All articles